IL7 and neoplasm: This suggests that T cell-based immunotherapies, such as ICIs, chimeric antigen receptor T cells (CAR-T), or bi-specific T cell engagers, may produce synergistic effects when combined with an autologous tumor cell vaccine loaded with IL-7-expressing NDV.